To explore the biomarker of primary resistance, we divided advanced NSCLC patients with EGFR 19 del or L858R mutations into two groups, one for aggressively progressive response and the other for slowly progressive response following first-line EGFR-TKI treatments. Here, EGFR is linked to non-small cell lung carcinoma.